Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06704685

A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI

This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether "butylphthalide +PCI" combined treatment mode on the basis of traditional drug therapy could reduce myocardial infarct size, improve cardiac function and long-term prognosis of patients with acute myocardial infarction, and verify the drug safety of butylphthalide in the treatment of STEMI within the window period of 12 hours.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age range of 18-75 years, encompassing both genders;
  • Patients presenting with an initial clinical diagnosis of acute ST-segment elevation myocardial infarction (STEMI), within a maximum time frame of 12 hours from the onset of pain to consideration for trial inclusion, who fulfill the criteria for percutaneous coronary intervention (PCI) and express their intention to undergo PCI;
  • The subject and their legal representative possess the capacity and willingness to provide informed consent by signing.

Exclusion criteria

  • Uncontrolled hypertension (systolic blood pressure≥200mmHg and/or diastolic blood pressure≥110mmHg);
  • Previous PCI or CABG;
  • Long-term use of loading doses of anticoagulant or antiplatelet drugs;
  • History of hemorrhagic stroke or ischemic stroke within 6 months, peptic ulcer, prolonged cardiopulmonary resuscitation (more than 10 minutes) within the last 6 weeks, surgery, or major trauma;
  • Known allergy to butylphthalide or excipients;
  • Patients with any of the following conditions: cardiogenic shock, chronic congestive heart failure NYHA class ≥III, severe hypotension, pulmonary insufficiency, severe hepatic and renal insufficiency;
  • History of congenital or acquired hemorrhagic diseases, coagulation factor deficiency diseases, thrombocytopenic diseases, etc. Or any of the following laboratory tests (INR > 2.0, platelet count < 100×109/L, Hb < 10g/dl);
  • Pregnancy, lactation, and planning to become pregnant within 30 days;
  • Severe mental disorder, alcohol dependence or inability to cooperate with informed consent and follow-up due to dementia;
  • Concurrent malignant tumor or severe systemic disease with expected survival time less than 30 days;
  • Have participated in or are currently participating in another clinical intervention study within 30 days before randomization;
  • Other reasons for not being eligible for the study.

Treatment and study plan

Butylphthalide

Drug

Subjects who were initially diagnosed with STEMI and scheduled for PCI were randomly assigned to one of two groups in a 1:1 ratio: a butylphthalide group and a placebo group.

Butylphthalide Placebo

Drug

Butylphthalide placebo

Primary outcomes

  1. The efficacy in reducing myocardial infarct size in subjects with STEMI after primary PCI

    Time frame: 30±2 days post-randomization

    To evaluate the efficacy of butylphthalide injection versus placebo in reducing myocardial infarct size at day 30 in patients with STEMI after primary PCI.

Secondary outcomes

  1. The proportion of no-reflow and severe slow flow events

    Time frame: 30±2 days post-randomization

    The proportion of no-reflow and severe slow flow events on day 30±2 after randomization (TFG<2 is defined as slow flow events and angiographic score).

  2. The changes of ST-segment resolution in electrocardiogram

    Time frame: 7±2 days and 30±2 days post-randomization

    ST-segment resolution of electrocardiogram at 7±2 days and 30±2 days after randomization.

  3. CMR imaging cardiac function indexes and cardiac color Doppler ultrasound related indexes

    Time frame: 30±2 days post-randomization

    CMR examination of microcirculation obstruction area, delayed enhancement phenomenon, left ventricular ejection fraction (LVEF%) and other CMR imaging cardiac function indicators and cardiac color Doppler ultrasound related indicators.

  4. The decline of myocardial enzyme indexes

    Time frame: 7±2 days and 30±2 days post-randomization

    Myocardial enzyme indexes (CK-MB, troponin I or T) decline at 7±2 days and 30±2 days of randomization.

  5. Proportion of combined vascular events

    Time frame: 30±2 days post-randomization

    Rate of combined vascular events (symptomatic stroke, recurrent myocardial infarction, vascular death) at 30±2 days after randomization.

Study contacts

Contact information is provided by the study sponsor or research team.

Le Zhang

CONTACT

[email protected]

86+13973187150

Sponsors and collaborators

Lead sponsor

Xiangya Hospital of Central South University

Other

Collaborators

  • CSPC Pharmaceutical Group Limited

Registry information

Official study title

A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI - A Prospective, Multicenter, Randomized, Placebo, Double-blinded End Trial.

Acronym: RISE

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 26, 2024
Registry last updated
Nov 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.